We demonstrated that targeted NGS using the QIAseq Human Breast Cancer Panel could detect the driver mutations in all cases of breast cancer examined, except for one case with a germline TP53 mutation that did not meet the classic criteria for Li–Fraumeni syndrome [18] or the Chompret criteria [19]. This evidence concerns the gene TP53 and breast cancer.